Jean-Eric Tarride - McMaster Experts

Affiliations

Faculty of Health Sciences, McMaster University
Member, Michael G. DeGroote Cochrane Canada Centre at McMaster, Faculty of Health Sciences
Member, Centre for Medicinal Cannabis Research (CMCR), Faculty of Health Sciences
Health Research Methods, Evidence, and Impact (Internal), Faculty of Health Sciences
Centre for Metabolism, Obesity, and Diabetes Research (MODR) (Internal), Faculty of Health Sciences
Centre for Medicinal Cannabis Research (CMCR) (Internal), Faculty of Health Sciences
Professor, Health Research Methods, Evidence, and Impact, Faculty of Health Sciences
Director, Centre for Health Economics and Policy Analysis (CHEPA), Faculty of Health Sciences
Member, Centre for Metabolism, Obesity, and Diabetes Research (MODR), Faculty of Health Sciences
Associate Member, Economics, Faculty of Social Sciences

Scholarly Activity in McMaster Experts

Co-author Network

Scholarly Activity
Teaching
Contact
View All

selected scholarly activity

conferences
- ASSESSMENT OF THE COST-EFFECTIVENESS OF RISK FACTOR GUIDED PROPHYLAXIS WITH PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN COLOMBIAN INFANTS BORN AT 32-35 WEEKS' GESTATIONAL AGE. Value in Health. S156-S156. 2023
- OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE. Value in Health. S125-S125. 2023
- A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB106-AB106. 2023
- A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB107-AB107. 2023
- A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB107-AB107. 2023
- A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. AB107-AB107. 2023
- ONE- AND FIVE-YEAR SURVIVAL AFTER FRAGILITY FRACTURE: REAL-WORLD RETROSPECTIVE MATCHED-COHORT STUDY IN ONTARIO, CANADA. Aging - Clinical and Experimental Research. S145-S145. 2023
- One- and five-year survival after fragility fracture: Real-world retrospective matched-cohort study in Ontario, Canada. Journal of Bone and Mineral Research. 80-81. 2023
- DEVELOPMENT AND APPLICATION OF A NEW COST-UTILITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS. Value in Health. S137-S138. 2022
- TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG GENERALIZED PUSTULAR PSORIASIS PATIENTS: A CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS. Value in Health. S228-S228. 2022
- TEN-YEAR EPIDEMIOLOGY, ECONOMIC BURDEN AND ALL-CAUSE MORTALITY AMONG PALMOPLANTAR PUSTOLOSIS PATIENTS: A 10-YEAR CANADIAN PREVALENCE STUDY OF INPATIENT CARE, EMERGENCY DEPARTMENTS, AND HOSPITAL- OR COMMUNITY-BASED OUTPATIENT CLINICS. Value in Health. S220-S220. 2022
- Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. S196-S196. 2022
- BARIATRIC SURGERY AS SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE: A POPULATION-BASED MATCHED COHORT STUDY IN A UNIVERSAL HEALTHCARE SYSTEM Cardiovascular risk and bariatric surgery. Obesity Surgery. 76-77. 2022
- THE SUSTAINED RISK OF OBESITY ON BREAST CANCER INCIDENCE AFTER SURGICAL WEIGHT LOSS: A POPULATION-BASED, MULTIPLE-MATCHED COHORT STUDY. Obesity Surgery. 558-558. 2022
- COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS. Value in Health. S428-S428. 2022
- Burden of Paget's Disease of Bone: Temporal Trend Over 20 years in Quebec, Canada. Journal of Bone and Mineral Research. 77-77. 2022
- Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. Blood. 4990-4990. 2021
- The Fragility Hip Fracture: Not only a Marked Burden of Disease, but also a Significant Predictor of Subsequent Hip Fracture Risk. Journal of Bone and Mineral Research. 225-226. 2020
- Real-world cost-effectiveness of direct oral anticoagulants in the Quebec setting. Pharmacoepidemiology and Drug Safety. 314-314. 2020
- REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. Journal of Bone and Mineral Research. 105-105. 2019
- REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. Journal of Bone and Mineral Research. 105-105. 2019
- Real-World Outcomes and Imminent Fractures After Index Fragility Fracture: A Population Study. Journal of Bone and Mineral Research. 105-105. 2019
- Real-World Outcomes and Imminent Fractures After Index Fragility Fracture: A Population Study. Journal of Bone and Mineral Research. 105-105. 2019
- ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS. Value in Health. S521-S521. 2019
- A simulation-based comparison of confounding adjustment methods in observational studies of administrative data. Pharmacoepidemiology and Drug Safety. 71-72. 2019
- The devil you should know: Adjustment for confounding bias is rare in observational economic evaluations in cardiology. Pharmacoepidemiology and Drug Safety. 303-304. 2019
- Outcomes from a Multicentre Pilot Randomized Clinical Trial of Early In-Bed Cycling with Mechanically Ventilated Patients: CYCLE Pilot RCT. American Journal of Respiratory and Critical Care Medicine. 2018
- MP11-14 COST EFFECTIVENESS OF TARGETED ANTIMICROBIAL THERAPY IN TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY. Investigative Urology. E142-E142. 2017
- Cycle Pilot Rct: A Multicenter Feasibility Study Of Early In-Bed Cycling Versus Routine Physiotherapy In Medical- Surgical Ventilated Patients. American Journal of Respiratory and Critical Care Medicine. 2017
- Indirect Costs Associated with Cardiovascular Disease in Canada: A Literature Review. Value in Health. A49-A49. 2016
- Propensity Score Matching Does not Always Remove Confounding within an Economic Evaluation Based on a Non-Randomized Study. Value in Health. A338-A338. 2015
- Psychiatric Healthcare Utilization and Related Costs in Newly Diagnosed Individuals with Autism Spectrum Disorder (ASD) in Quebec (Canada). Pharmacoepidemiology and Drug Safety. 278-279. 2015
- Concomitant Use of Non-Steroidal Anti-Inflammatory Drugs (Nsaids) And Proton Pump Inhibitors (Ppis) in Newly Diagnosed Patients With Osteoarthritis (Oa), Rheumatoid Arthritis (Ra) or Ankylosing Spondylitis (As). Value in Health. A390-A390. 2014
- Follow-Up of Psychoactive Drug Use in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada). Pharmacoepidemiology and Drug Safety. 95-96. 2014
- Psychiatric Health Care Utilisation and Related Costs in Newly Diagnosed Patients with Autism Spectrum Disorder (ASD) in Quebec (Canada). Pharmacoepidemiology and Drug Safety. 280-280. 2014
- A systematic review of methodological frameworks for evaluation of ethical considerations in health technology assessment. Value in Health. A200-A200. 2014
- Follow-Up Of Psychoactive Drug Use In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada). Value in Health. A155-A156. 2014
- Psychiatric Health Care Utilisation And Related Costs In Newly Diagnosed Patients With Autism Spectrum Disorder (Asd) In Quebec (Canada). Value in Health. A158-A158. 2014
- Assessment of a Canadian Primary Care Electronic Medical Record Database for Use in Observational Studies. Value in Health. A582-A582. 2013
- Psychoactive Drug Use, Polypharmacy and Co-Morbidities in Newly Diagnosed Patients with Pervasive Development Disorder in the Province of Quebec. Value in Health. A552-A552. 2013
- Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome. Journal of Clinical Endocrinology and Metabolism (JCEM). E1072-E1087. 2013
- How can we use discrete event simulation to improve access to health care: an assessment of increasing access to care for children with medically refractory epilepsy. Value in Health. A108-A109. 2013
- CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA. Value in Health. A495-A496. 2012
- PDB34 Economic Evaluation of Treating Diabetes Patients According to Guidelines in South-Western Ontario, Canada. Value in Health. A499-A499. 2012
- PDB77 Characteristics of Patients With Diabetes in Southwestern Ontario, Canada. Value in Health. A507-A507. 2012
- PHP202 Bridging the Gap Between Institutional Levels Using Systems Analysis. Value in Health. A325-A325. 2012
- Relative, Reliability-Adjusted Diagnostic Test Accuracy of Erosion Detection Between Magnetic Resonance Imaging and Radiography in Rheumatoid Arthritis. Arthritis and Rheumatism. S888-S888. 2012
- The Effect of Evaluation Variability At the Unit of Measurement On the Reliability of Omeract Ramris and Van Der Heijde-Modified Sharp Score.. Arthritis and Rheumatism. S440-S440. 2012
- PMD8 Efficacy of Systemic Hyperbaric Oxygen Therapy for Non-Healing Diabetic Ulcers of the Lower Limb: Systematic Review and Meta-Analysis. Value in Health. A63-A63. 2012
- PRM28 Physicians as Pseudo-Agents in a Hospital Emergency Department Discrete Event Simulation. Value in Health. A163-A163. 2012
- 2015 CHANGES IN ERECTILE FUNCTION AFTER PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA. Investigative Urology. E813-E814. 2012
- PCN175 Reimbursement of Anticancer Drugs in Canada: What Can We Learn from the Nice New Appraisal Process for Life-Extending End-of-Life Treatments?. Value in Health. A466-A466. 2011
- PCV50 Hospital Costs Associated with Atrial Fibrillation in Canada. Value in Health. A373-A373. 2011
- PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies. Value in Health. A260-A260. 2011
- PMH26 Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model. Value in Health. A291-A291. 2011
- PMS22 The Burden of Illness of Osteoporosis in Canada. Value in Health. A306-A306. 2011
- Direct Cost of Schizophrenia in Quebec, Canada: An Incidence-Based Microsimulation Monte-Carlo Markov Model. Pharmacoepidemiology and Drug Safety. S195-S195. 2011
- PIN34 INTRANASAL LIVE ATTENUATED (LAIV) VERSUS INJECTABLE INACTIVATED (TIV) INFLUENZA VACCINE FOR CHILDREN AND ADOLESCENTS: A CANADIAN COST EFFECTIVENESS ANALYSIS. Value in Health. A119-A120. 2011
- PSY48 A WORKPLACE HEALTH PROGRAM FOR BRITISH COLUMBIA PUBLIC SERVICE AGENCY (CANADA). Value in Health. A68-A68. 2011
- PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Value in Health. A75-A75. 2011
- PMS21 THE ACUTE CARE COSTS OF OSTEOPOROSIS-RELATED FRACTURES IN CANADA. Value in Health. A306-A306. 2010
- Factors Associated with the Schizophrenia Specific States: A Population-Based Study. Pharmacoepidemiology and Drug Safety. S274-S275. 2010
- Validation of a Monte-Carlo Markov Model for Schizophrenia. Pharmacoepidemiology and Drug Safety. S153-S154. 2010
- HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO. Value in Health. A133-A133. 2010
- PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY. Value in Health. A211-A211. 2010
- UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO. Value in Health. A133-A134. 2010
- DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES. Value in Health. A234-A234. 2009
- MC6 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION. Value in Health. A488-A489. 2009
- MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R. Value in Health. A226-A227. 2009
- PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS. Value in Health. A405-A405. 2009
- PMC35 SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO MICROSIMULATION. Value in Health. A393-A393. 2009
- PMH18 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE. Value in Health. A353-A353. 2009
- PMH2 SCHIZOPHRENIA MODELING: FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE. Value in Health. A520-A520. 2009
- PND31 HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMER'S DISEASE HEALTH STATE: A CANADIAN SURVEY OF THE GENERAL PUBLIC. Value in Health. A371-A371. 2009
- PND47 ASSESSING CANADIANS' WILLINGNESS-TO-PAY FOR ALZHEIMER'S DISEASE MEDICATIONS. Value in Health. A374-A374. 2009
- PND48 SUPPORT FOR PROVIDING UNRESTRICTED ACCESS TO AN ALZHEIMER'S DISEASE MEDICATION IN CANADA: RESULTS FROM A STUDY OF THE GENERAL POPULATION. Value in Health. A374-A375. 2009
- PSY18 THE BURDEN OF OBESITY IN ONTARIO. Value in Health. A378-A378. 2009
- PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS. Value in Health. A58-A58. 2009
- PND26 UTILITIES FOR MODERATE ALZHEIMER'S DISEASE: RESULTS FROM A SURVEY OF THE GENERAL PUBLIC IN CANADA. Value in Health. A194-A194. 2009
- PSY9 USING UTILIZATION RECORDS TO ESTIMATE THE BURDEN OF OBESITY IN ADULTS LIVING IN ONTARIO. Value in Health. A131-A131. 2009
- QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA. Value in Health. A17-A17. 2009
- PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?. Value in Health. A51-A51. 2008
- PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS. Value in Health. A173-A174. 2008
- PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT. Value in Health. A265-A265. 2008
- Clinical and autonomic predictors for head-up tilt table test response in patients with suspected vasovagal syncope. Canadian Journal of Cardiology. 63C-63C. 2007
- PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS. Value in Health. A361-A361. 2006
- CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA. Value in Health. A8-A8. 2006
- PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL. Value in Health. A33-A34. 2006
- PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY. Value in Health. A36-A36. 2006
- PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?. Value in Health. A56-A56. 2006
- PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA). Value in Health. A173-A173. 2006
- Current prevalence and control of dyslipidemia in the primary care setting. Circulation. E355-E355. 2005
- Prescription choices for treatment and control of dyslipidemia in primary care. Circulation. E355-E355. 2005
journal articles
- Cost-Utility Analysis of Low-Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack.. Journal of the American Heart Association. 13:e034531. 2024
- Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses. PharmacoEconomics - Open. 8:823-836. 2024
- Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers' Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses.. PharmacoEconomics - Open. 8:963-965. 2024
- Systematic methodological review of health state values in glaucoma cost-utility analyses. European Journal of Health Economics. 25:1417-1435. 2024
- Economic evaluation of the “paramedics and palliative care: bringing vital services to Canadians” program compared to the status quo. Canadian Journal of Emergency Medicine. 26:671-680. 2024
- A scoping review of costing methodologies used to assess interventions for underserved pregnant people and new parents.. International Journal for Equity in Health. 23:168. 2024
- Cost Evaluation of the Ontario Virtual Urgent Care Pilot Program: Population-Based, Matched Cohort Study. Journal of Medical Internet Research. 26:e50483-e50483. 2024
- Cost-effectiveness analysis of health tapestry, a complex primary care program for older adults: a post-hoc analysis. BMC Primary Care. 25:235. 2024
- Early In-Bed Cycle Ergometry in Mechanically Ventilated Patients. NEJM Evid. 3:EVIDoa2400137. 2024
- ROBVALU: a tool for assessing risk of bias in studies about people’s values, utilities, or importance of health outcomes. The BMJ. 385:e079890-e079890. 2024
- Scoping review of the recommendations and guidance for improving the quality of rare disease registries. Orphanet Journal of Rare Diseases. 19:187. 2024
- Coordination of oral anticoagulant care at hospital discharge (COACHeD): pilot randomised controlled trial. BMJ Open. 14:e079353-e079353. 2024
- Improving medication prescribing-related outcomes for vulnerable elderly in transitions on high-risk medications (IMPROVE-IT HRM): a pilot randomized trial protocol. Pilot and Feasibility Studies. 10:60. 2024
- Economic evaluation of non-invasive liver tests for the diagnosis of liver fibrosis in chronic liver diseases: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. 22:681-688. 2024
- Postfracture survival in a population-based study of adults aged ≥66 yr: a call to action at hospital discharge. JBMR Plus. 8:ziae002. 2024
- Robot-assisted partial knee replacement versus standard total knee replacement (RoboKnees): a protocol for a pilot randomized controlled trial. Pilot and Feasibility Studies. 10:39. 2024
- Opioid reduction and enhanced recovery in orthopaedic surgery (OREOS): a protocol for a feasibility randomised controlled trial in patients undergoing total knee arthroplasty. Pilot and Feasibility Studies. 10:30. 2024
- Assessing the feasibility of an integrated collection of education modules for fall and fracture prevention (iCARE) for healthcare providers in long term care: A longitudinal study.. PLOS Global Public Health. 4:e0003096. 2024
- Association between children’s caregivers time preferences and childhood overweight and obesity in Mexico. PLoS ONE. 19:e0283455-e0283455. 2024
- Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials. BMJ Open. 14:e068182-e068182. 2024
- The relationship between patient experience and real-world digital health access in primary care: A population-based cross-sectional study. PLoS ONE. 19:e0299005-e0299005. 2024
- Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. Journal of Medical Economics. 26:630-643. 2023
- EE390 Optimizing the Use of Risk Factors to Guide the Cost-Effective Use of Palivizumab Prophylaxis Against Severe Respiratory Syncytial Virus Infection in Korean Infants Born 32–35 Weeks’ Gestational Age. Value in Health. 26:S125-S125. 2023
- EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age. Value in Health. 26:S156-S156. 2023
- Health care utilization and outcomes of patients seen by virtual urgent care versus in-person emergency department care. CANADIAN MEDICAL ASSOCIATION JOURNAL. 195:E1463-E1474. 2023
- Prevalence and incidence of Paget's disease of bone: Temporal trend over 20 years in the province of Quebec, Canada. Bone. 176:116895-116895. 2023
- Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis. 7:102228-102228. 2023
- 50 New Analysis on the Cost-effectiveness of Palivizumab (PVZ) for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Canadian Infants Born 29-31 and 32-35 weeks’ Gestational Age (wGA). Paediatrics and Child Health. 28:e22-e22. 2023
- Motivational interviewing to promote healthy behaviors for obesity prevention in young adults (MOTIVATE): a pilot randomized controlled trial protocol. Pilot and Feasibility Studies. 9:156. 2023
- 43266 A 10-year population-based prevalence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB106-AB106. 2023
- 43322 A 10-year population-based prevalence study of the burden of palmoplantar pustulosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB107-AB107. 2023
- 44100 A 3-year population-based incidence study of the burden of generalized pustular psoriasis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB107-AB107. 2023
- 44118 A 3-year population-based incidence study of the burden of palmoplantar pustolosis in Canadian patients hospitalized or seen in emergency departments and hospital- or community-based outpatient clinics. Journal of American Academy of Dermatology. 89:AB107-AB107. 2023
- The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics. JAAD Int. 12:90-98. 2023
- The burden of palmoplantar pustulosis: A Canadian population-based study of inpatient care, emergency departments, and outpatient clinics. JAAD Int. 12:151-159. 2023
- A longitudinal study evaluating adverse childhood experiences and obesity in adulthood using the Canadian Longitudinal Study on Aging (CLSA). International Journal of Epidemiology. 52:1100-1111. 2023
- Resurrecting Multiattribute Utility Function: Developing a Value Set for Health Utility for Glaucoma. Value in Health. 26:1249-1257. 2023
- Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data. Current Oncology. 30:6596-6608. 2023
- Critical Care Cycling to ImproveLowerExtremity Strength (CYCLE): protocol for an international, multicentre randomised clinical trial of early in-bed cycling for mechanically ventilated patients. BMJ Open. 13:e075685-e075685. 2023
- Molecular test of Paget's disease of bone in families not linked to SQSTM1 gene mutations. Bone Reports. 18:101670-101670. 2023
- Residual Risk of Breast Cancer After Bariatric Surgery. JAMA Surgery. 158:634-634. 2023
- Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants. Journal of Infectious Diseases. 227:1333-1334. 2023
- Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective. Current Oncology. 30:4688-4699. 2023
- Health TAPESTRY Ontario: A Multi-Site Randomized Controlled Trial Testing Implementation and Reproducibility. Annals of Family Medicine. 21:132-142. 2023
- Obesity and adverse childhood experiences in relation to stress during the COVID-19 pandemic: an analysis of the Canadian Longitudinal Study on Aging. International Journal of Obesity. 47:197-206. 2023
- Return on investment of Canadian tobacco control policies implemented between 2001 and 2016. Tobacco Control. 32:233-238. 2023
- Health Utilities Index Mark 3 scores for children and youth: Population norms for Canada based on cycles 5 (2016 and 2017) and 6 (2018 and 2019) of the Canadian Health Measures Survey.. Health Reports. 34:29-39. 2023
- Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS): A Protocol for a Feasibility Randomized Controlled Trial in Knee Replacement Patients 2023
- A multi-center, randomized, 12-month, parallel-group, feasibility study to assess the acceptability and preliminary impact of family navigation plus usual care versus usual care on attrition in managing pediatric obesity: a study protocol. Pilot and Feasibility Studies. 9:14. 2023
- A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age. PLoS ONE. 18:e0289828-e0289828. 2023
- Demographic characteristics, outcomes and experience of patients using virtual urgent care services from 14 emergency department led sites in Ontario. Canadian Journal of Emergency Medicine. 25:65-73. 2023
- What are effective strategies to respond to the psychological impacts of working on the frontlines of a public health emergency?. Frontiers in Public Health. 11:1282296. 2023
- “It saved me from the emergency department”: A qualitative study of patient experience of virtual urgent care in Ontario. PLoS ONE. 18:e0285468-e0285468. 2023
- Opioid reduction and enhanced recovery in orthopaedic surgery (OREOS): A feasibility randomized controlled trial in knee replacement patients. Canadian Journal of Pain. 6:1-2. 2022
- A scoping review of strategies to support public health recovery in the transition to a “new normal” in the age of COVID-19. BMC International Health and Human Rights. 22:1244. 2022
- Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trial. Pilot and Feasibility Studies. 8:166. 2022
- EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants. Value in Health. 25:S137-S138. 2022
- EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S220-S220. 2022
- EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S228-S228. 2022
- EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S196-S196. 2022
- EPH46 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics. Value in Health. 25:S200-S200. 2022
- Defining the Assisted Living Sector in Canada: An Environmental Scan. Journal of the American Medical Directors Association. 23:1871-1877.e1. 2022
- Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia. Current Oncology. 29:7624-7636. 2022
- Economic Evaluation of Early Psychosis Interventions From A Canadian Perspective. Canadian Journal of Psychiatry. 67:768-777. 2022
- Reverse Total Shoulder Arthroplasty Is the Most Cost-effective Treatment Strategy for Proximal Humerus Fractures in Older Adults: A Cost-utility Analysis. Clinical Orthopaedics and Related Research. 480:2013-2026. 2022
- The treatment of epilepsy in younger and older adults: Demographic differences and prescribing patterns of anti-seizure medications in Canada. Epilepsy Research. 184:106941-106941. 2022
- EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors. Value in Health. 25:S428-S428. 2022
- A review of implementation and evaluation of Pan American Health Organization's policies to prevent childhood obesity in Latin America. Obesity Science and Practice. 8:352-362. 2022
- Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry. 12:214. 2022
- Rates of health services use among residents of retirement homes in Ontario: a population-based cohort study. CANADIAN MEDICAL ASSOCIATION JOURNAL. 194:E730-E738. 2022
- A comparison of confounder selection and adjustment methods for estimating causal effects using large healthcare databases. Pharmacoepidemiology and Drug Safety. 31:424-433. 2022
- Bariatric Surgery and Breast Cancer Incidence: a Population-Based, Matched Cohort Study. Obesity Surgery. 32:1261-1269. 2022
- Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry. 12:101. 2022
- Virologic failure in people living with HIV in 1st line ART: A 10-year Mexican population-based study. International Journal of STD and AIDS. 33:363-373. 2022
- Continuous Noninvasive Remote Automated Blood Pressure Monitoring With Novel Wearable Technology: A Preliminary Validation Study. JMIR mHealth and uHealth. 10:e24916-e24916. 2022
- Challenges of Conducting Value Assessment for Comprehensive Genomic Profiling. International Journal of Technology Assessment in Health Care. 38:e57. 2022
- Economic Evaluation of Palliative Care Interventions: A Review of the Evolution of Methods From 2011 to 2019. American Journal of Hospice and Palliative Medicine. 39:108-122. 2022
- Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. Osteoporosis International. 33:113-122. 2022
- Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID). PLoS ONE. 17:e0266663-e0266663. 2022
- Do assisted living facilities that offer a dementia care program differ from those that do not? A population-level cross-sectional study in Ontario, Canada. BMC Geriatrics. 21:463. 2021
- Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. BMC Musculoskeletal Disorders. 22:105. 2021
- Patient characteristics and determinants of CD4 at diagnosis of HIV in Mexico from 2008 to 2017: a 10-year population-based study. AIDS Research and Therapy. 18:84. 2021
- Team approach to polypharmacy evaluation and reduction: study protocol for a randomized controlled trial. Trials. 22:746. 2021
- Association Between Dementia Care Programs in Assisted Living Facilities and Transitions to Nursing Homes in Ontario, Canada: A Population-Based Cohort Study. Journal of the American Medical Directors Association. 22:2115-2120.e6. 2021
- The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. Current Oncology. 28:3649-3658. 2021
- Comparison of 4-Year Health Care Expenditures Associated With Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. JAMA network open. 4:e2122079-e2122079. 2021
- Health programmes and services addressing the prevention and management of infectious diseases in people who inject drugs in Canada: a systematic integrative review. BMJ Open. 11:e047511-e047511. 2021
- Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada. Osteoporosis International. 32:1753-1761. 2021
- Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology. PharmacoEconomics - Open. 5:397-410. 2021
- Unrecognized assets created by public-sector investments in health and social services. Journal of Public Budgeting, Accounting and Financial Management. 33:409-426. 2021
- Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:. Circulation. 143:1468-1480. 2021
- Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. JAMA network open. 4:e216820-e216820. 2021
- The Need for an Improved Evidence Base to Inform the Health Care Decision-making Process—Reply. JAMA Surgery. 156:399-399. 2021
- Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskeletal Disorders. 22:224. 2021
- Do Assisted Living Facilities That Offer a Dementia Care Program Differ from Those That Do Not? A Population-Level Cross-Sectional Study in Ontario, Canada 2021
- GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making. Journal of Clinical Epidemiology. 129:138-150. 2021
- Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. Journal of Medical Economics. 24:1318-1326. 2021
- Medication use and its impact on high-cost health care users among older adults: protocol for the population-based matched cohort HiCOSTT study. CMAJ open. 9:E44-E52. 2021
- One-Year Costs Associated with Hospitalizations Due to Aortic Stenosis in Canada. CJC OPEN. 3:82-90. 2021
- The impact of routine HIV drug resistance testing in Ontario: A controlled interrupted time series study. PLoS ONE. 16:e0246766-e0246766. 2021
- Health TAPESTRY Ontario: protocol for a randomized controlled trial to test reproducibility and implementation. Trials. 21:714. 2020
- Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators. BMC Cancer. 20:795. 2020
- Association Between Bariatric Surgery and All-Cause Mortality: A Population-Based Matched Cohort Study in a Universal Health Care System. ACP journal club. 173:694-703. 2020
- Is Total Hip Arthroplasty a Cost-Effective Option for Management of Displaced Femoral Neck Fractures? A Trial-Based Analysis of the HEALTH Study. Journal of Orthopaedic Trauma. 34:S37-S41. 2020
- Association of Roux-en-Y Gastric Bypass With Postoperative Health Care Use and Expenditures in Canada. JAMA Surgery. 155:e201985-e201985. 2020
- Economic evaluation of robot-assisted radical prostatectomy compared to open radical prostatectomy for prostate cancer treatment in Ontario, Canada. Journal of the Canadian Urological Association. 14:E350-E357. 2020
- Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol. BMJ Open. 10:e035188-e035188. 2020
- A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017. Medical decision making. 40:582-595. 2020
- Health TAPESTRY Ontario: Protocol for a Randomized Controlled Trial to Test Reproducibility and Implementation 2020
- Methodological approaches to the design and analysis of nonrandomized intervention studies for the prevention of child and adolescent obesity. Canadian Journal of Public Health. 111:358-370. 2020
- Health TAPESTRY Ontario: Protocol for a Randomized Controlled Trial to Test Reproducibility and Implementation 2020
- The hidden cost of an extensive preoperative work-up: predictors of attrition after referral for bariatric surgery in a universal healthcare system. Surgical Endoscopy. 34:988-995. 2020
- Stakeholders’ feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines. Journal of Population Therapeutics and Clinical Pharmacology. 27:e1-e24. 2020
- Health TAPESTRY Ontario: Protocol for a Randomized Controlled Trial to Test Replicability and Implementation 2019
- A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers. PharmacoEconomics - Open. 3:437-451. 2019
- PCN438 ECONOMIC EVALUATION METHODS IN ONCOLOGY: ONWARDS AND UPWARDS. Value in Health. 22:S521-S521. 2019
- Use, costs, and predictors of psychiatric healthcare services following an autism spectrum diagnosis: Population-based cohort study. Autism. 23:2020-2030. 2019
- Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. BMJ Open. 9:e028637-e028637. 2019
- Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. CMAJ open. 7:E537-E545. 2019
- PMS52 REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA. Value in Health. 22:S248-S248. 2019
- Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: A systematic review and network meta-analysis. Clinical and Investigative Medicine. 42:E53-E65. 2019
- Impact of Psychoactive Drug Use on Developing Obesity among Children and Adolescents with Autism Spectrum Diagnosis: A Nested Case–Control Study. Childhood Obesity. 15:131-141. 2019
- Multicentre pilot randomised clinical trial of early in-bed cycle ergometry with ventilated patients. BMJ Open Respiratory Research. 6:e000383-e000383. 2019
- <p>A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients</p>. ClinicoEconomics and Outcomes Research. Volume 11:477-486. 2019
- <p>Electronic referral systems in health care: a scoping review</p>. ClinicoEconomics and Outcomes Research. Volume 11:325-333. 2019
- Descriptive analysis of pharmacy services provided after community pharmacy screening. International Journal of Clinical Pharmacy. 40:1577-1586. 2018
- Direct Health-Care Costs and Productivity Costs Associated With Hypoglycemia in Adults With Type 1 and Type 2 Diabetes Mellitus That Participated in the Canadian Hypoglycemia Assessment Tool Program. Canadian Journal of Diabetes. 42:659-663. 2018
- Health Utilities Index Mark 3 scores for major chronic conditions: Population norms for Canada based on the 2013 and 2014 Canadian Community Health Survey.. Health Reports. 29:12-19. 2018
- Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?. Canadian Journal of Cardiology. 34:1522-1525. 2018
- Regional variation in healthcare spending and mortality among senior high-cost healthcare users in Ontario, Canada: a retrospective matched cohort study. BMC Geriatrics. 18:262-262. 2018
- Effectiveness of a Type 2 Diabetes Screening Intervention in the Canadian Workplace. Canadian Journal of Diabetes. 42:493-499.e1. 2018
- Cognitive Impairment Mediates Workplace Impairment in Adults With Type 2 Diabetes Mellitus: Results From the Motivaction Study. Canadian Journal of Diabetes. 42:289-295. 2018
- Managing High‐Cost Healthcare Users: The International Search for Effective Evidence‐Supported Strategies. Journal of The American Geriatrics Society. 66:1002-1008. 2018
- Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada. PharmacoEconomics - Open. 2:19-29. 2018
- Age- and sex-specific Canadian utility norms, based on the 2013–2014 Canadian Community Health Survey. CANADIAN MEDICAL ASSOCIATION JOURNAL. 190:E155-E161. 2018
- A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. ClinicoEconomics and Outcomes Research. Volume 10:821-854. 2018
- Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research. Volume 10:127-137. 2018
- Just how much does it cost? A cost study of chronic pain following cardiac surgery. Journal of Pain Research. Volume 11:2741-2759. 2018
- PP51 Updating Canadian Pharmaceutical Budget Impact Analysis Guidelines. International Journal of Technology Assessment in Health Care. 34:86-86. 2018
- Senior high-cost healthcare users’ resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada. BMJ Open. 7:e018488-e018488. 2017
- Low-intensity pulsed ultrasound for treatment of tibial fractures. The Bone & Joint Journal. 99-B:1526-1532. 2017
- Low-intensity pulsed ultrasound for treatment of tibial fractures AN ECONOMIC EVALUATION OF THE TRUST STUDY. The Bone & Joint Journal. 99B:1526-1532. 2017
- Effectiveness of a Diabetes Screening Intervention in the Canadian Workplace. Canadian Journal of Diabetes. 41:S28-S28. 2017
- CGS 37th Annual Scientific Meeting: Integrating Care, Making an Impact. Canadian Geriatrics Journal. 20:198-239. 2017
- Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ open. 5:E653-E661. 2017
- Increase in Psychoactive Drug Prescriptions in the Years Following Autism Spectrum Diagnosis: A Population-Based Cohort Study. Journal of Population Therapeutics and Clinical Pharmacology. 24:e19-e32. 2017
- SENIOR HIGH COST HEALTHCARE USERS: HOW DO THEY DIFFER?. Innovation in Aging. 1:55-55. 2017
- What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review. Journal of Population Therapeutics and Clinical Pharmacology. 24:e1-e20. 2017
- Erratum to: The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. Obesity Surgery. 27:1128-1128. 2017
- The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. Obesity Surgery. 27:349-356. 2017
- Correction: Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis. Journal of Clinical Medicine Research. 9:231-231. 2017
- Illustration of the Impact of Unmeasured Confounding Within an Economic Evaluation Based on Nonrandomized Data. MDM Policy and Practice. 2:238146831769771-238146831769771. 2017
- Preliminary Results of the Adoption and Application of the Integrated Comprehensive Care Bundle Care Program When Treating Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal. 2017:1-10. 2017
- A comparison of health utility scores calculated using United Kingdom and Canadian preference weights in persons with alzheimer’s disease and their caregivers. Health and Quality of Life Outcomes. 14:105. 2016
- Loss of health related quality of life following low-trauma fractures in the elderly. BMC Geriatrics. 16:84. 2016
- Steps toward improving ethical evaluation in health technology assessment: a proposed framework. BMC Medical Ethics. 17:34. 2016
- The current economic burden of illness of osteoporosis in Canada. Osteoporosis International. 27:3023-3032. 2016
- A population-based analysis of the drivers of short-term costs after bariatric surgery within a publicly funded regionalized center of excellence system. Surgery for Obesity and Related Diseases. 12:1023-1031. 2016
- CYCLE pilot: a protocol for a pilot randomised study of early cycle ergometry versus routine physiotherapy in mechanically ventilated patients. BMJ Open. 6:e011659-e011659. 2016
- Summary of Glaucoma Diagnostic Testing Accuracy: An Evidence-Based Meta-Analysis. Journal of Clinical Medicine Research. 8:641-649. 2016
- Bridging the Gap between Evidence and Practice for Adults with Medically Refractory Temporal Lobe Epilepsy: Is a Change in Funding Policy Needed to Stimulate a Shift in Practice?. Epilepsy Research and Treatment. 2015:1-10. 2015
- Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations. BMC Research Notes. 8:244. 2015
- Psychiatric Healthcare Utilization and Related Costs In Newly Diagnosed Individuals With Autism Spectrum Disorder (Asd) In Quebec (Canada). Value in Health. 18:A746-A747. 2015
- Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies. Expert Review of Pharmacoeconomics and Outcomes Research. 15:451-463. 2015
- BARRIERS AND FACILITATORS INFLUENCING ETHICAL EVALUATION IN HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care. 31:113-123. 2015
- Caregivers’ willingness-to-pay for Alzheimer’s disease medications in Canada. Dementia. 14:63-79. 2015
- Impact on Health‐Related Quality of Life and Costs of Managing Chronic Neuropathic Pain in Academic Pain Centres: Results from a One‐Year Prospective Observational Canadian Study. Pain Research and Management. 20:327-333. 2015
- A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. Trials. 15:268. 2014
- P2‐325: A COMPARISON OF HEALTH UTILITY SCORES CALCULATED USING UNITED KINGDOM AND CANADIAN PREFERENCE WEIGHTS IN AN ALZHEIMER'S DISEASE SAMPLE. Alzheimer's and Dementia. 10:p598-p598. 2014
- Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research. 14:203-220. 2014
- Health Utility Scores in Alzheimer’s Disease: Differences Based on Calculation With American and Canadian Preference Weights. Value in Health. 17:77-83. 2014
- Access to surgery for paediatric patients with medically refractory epilepsy: A systems analysis. Epilepsy Research. 107:286-296. 2013
- Simulating an emergency department: the importance of modeling the interactions between physicians and delegates in a discrete event simulation. BMC Medical Informatics and Decision Making. 13:59. 2013
- Patients’ Willingness-to-Pay for an Alzheimer’s Disease Medication in Canada. Patient. 6:161-168. 2013
- HYPERBARIC OXYGEN THERAPY FOR DIABETIC ULCERS: SYSTEMATIC REVIEW AND META-ANALYSIS. International Journal of Technology Assessment in Health Care. 29:269-281. 2013
- Do Canadian Researchers and the Lay Public Prioritize Biomedical Research Outcomes Equally? A Choice Experiment. Academic Medicine. 88:519-526. 2013
- The Impact of Using Informative Priors in a Bayesian Cost-Effectiveness Analysis. Medical decision making. 33:437-450. 2013
- Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. Osteoporosis International. 24:581-593. 2013
- The Burden of Atrial Fibrillation on the Hospital Sector in Canada. Canadian Journal of Cardiology. 29:229-235. 2013
- A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. Journal of the Canadian Urological Association. 7:335-335. 2013
- Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney disease. Journal of the Canadian Urological Association. 7:108-13. 2013
- Photoselective vaporization for the treatment of benign prostatic hyperplasia.. Ontario Health Technology Assessment Series. 13:1-34. 2013
- The excess burden of rheumatoid arthritis in Ontario, Canada.. Clinical and Experimental Rheumatology. 31:18-24. 2013
- Economic Evaluations Conducted for Assessment of Genetic Testing Technologies: A Systematic Review. Genetic Testing and Molecular Biomarkers. 16:1322-1335. 2012
- PDB14 Characteristics of the Aboriginal People with Diabetes in the South-Western of Ontario, Canada. Value in Health. 15:A495-A496. 2012
- The General Publicʼs Willingness to Pay for Tax Increases to Support Unrestricted Access to an Alzheimerʼs Disease Medication. PharmacoEconomics (Auckland). 30:1085-1095. 2012
- The burden of illness of osteoporosis in Canada. Osteoporosis International. 23:2591-2600. 2012
- The burden of illness of osteoporosis in Canadian men. Journal of Bone and Mineral Research. 27:1830-1838. 2012
- P3‐312: The association between caregiver and patient health‐related quality‐of‐life in Alzheimer's disease. Alzheimer's and Dementia. 8:p568-p569. 2012
- Modeling cost–effectiveness of pharmaceuticals in Alzheimer's disease. Expert Review of Pharmacoeconomics and Outcomes Research. 12:275-277. 2012
- The economics of health information technology in medication management: a systematic review of economic evaluations. Journal of the American Medical Informatics Association : JAMIA. 19:423-438. 2012
- MATHEMATICAL MODELING: THE CASE OF EMERGENCY DEPARTMENT WAITING TIMES. International Journal of Technology Assessment in Health Care. 28:93-109. 2012
- Patient Management, and Time and Health Care Resource Utilization Associated with the Use of Intravenous Bisphosphonates For Patients with Metastatic Bone Disease: A Delphi Study. Hospital Practice. 40:131-137. 2012
- The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis and Rheumatism. 64:1153-1161. 2012
- Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporosis International. 23:921-927. 2012
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. Journal of Crohn's and Colitis. 6:77-85. 2012
- Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.. Journal of Population Therapeutics and Clinical Pharmacology. 19:e166-e178. 2012
- Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. ClinicoEconomics and Outcomes Research. 4:287-287. 2012
- Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada. ClinicoEconomics and Outcomes Research. 4:21-21. 2012
- A prospective, double-blind, randomized, controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus: a study protocol. Trials. 12:69. 2011
- Calculating Utility Decrements Associated With an Adverse Event. Medical decision making. 31:790-799. 2011
- Calculating Utility Decrements Associated With an Adverse Event: Marginal Tobit and CLAD Coefficients Should Be Used With Caution. Medical decision making. 31:790-799. 2011
- Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-Analysis. Seminars in Arthritis and Rheumatism. 41:178-186. 2011
- Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. Expert Review of Pharmacoeconomics and Outcomes Research. 11:513-521. 2011
- Health economic evaluations help inform payers of the best use of scarce health care resources.. International Journal of Circumpolar Health. 70:417-427. 2011
- Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Quality of Life Research. 20:939-943. 2011
- P3‐407: Patients’ and caregivers’ willingness to pay for a new Alzheimer's disease medication. Alzheimer's and Dementia. 7:s645-s646. 2011
- Ontario Multidetector Computed Tomographic Coronary Angiography Study. JAMA Internal Medicine. 171:1021-1029. 2011
- Health economic evaluations help inform payers of the best use of scarce health care resources. International Journal of Circumpolar Health. 70:419-427. 2011
- New glaucoma diagnostic technologies: a systematic review of economic studies. Canadian Journal of Ophthalmology. 46:89-91. 2011
- Bayesian Hierarchical Models Combining Different Study Types and Adjusting for Covariate Imbalances: A Simulation Study to Assess Model Performance. PLoS ONE. 6:e25635-e25635. 2011
- How Does the Canadian General Public Rate Moderate Alzheimer's Disease?. Journal of Aging Research. 2011:1-8. 2011
- Partnership in employee health. A workplace health program for British Columbia Public Service Agency (Canada). Work. 40:459-471. 2011
- Should Endovascular Repair Be Reimbursed for Low Risk Abdominal Aortic Aneurysm Patients? Evidence from Ontario, Canada. International Journal of Vascular Medicine. 2011:1-10. 2011
- Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEconomics and Outcomes Research. 3:89-89. 2011
- The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms. BMC Medical Research Methodology. 10:64. 2010
- Canadian Surgery Forum.. Canadian Journal of Surgery. 53:S51-S104. 2010
- General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Review of Pharmacoeconomics and Outcomes Research. 10:379-384. 2010
- Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. Value in Health. 13:487-494. 2010
- Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. Value in Health. 13:S8-S11. 2010
- PMS58 HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO. Value in Health. 13:A133-A133. 2010
- PMS60 UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO. Value in Health. 13:A133-A134. 2010
- Reply by the Authors. Urology. 75:1236-1237. 2010
- Systematic Review and Meta-analysis of Transurethral Resection of the Prostate Versus Minimally Invasive Procedures for the Treatment of Benign Prostatic Obstruction. Urology. 75:1015-1022. 2010
- A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. PharmacoEconomics (Auckland). 28:255-277. 2010
- An economic evaluation of surgery versus collagen injection for the treatment of female stress urinary incontinence.. Canadian Journal of Urology. 17:5087-5093. 2010
- Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature. Value in Health. 13:328-334. 2010
- Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study. European Journal of Health Economics. 11:27-34. 2010
- A review of health utilities across conditions common in paediatric and adult populations. Health and Quality of Life Outcomes. 8:12-12. 2010
- Capacity Constraints and Cost-Effectiveness: A Discrete Event Simulation for Drug-Eluting Stents. Medical decision making. 30:16-28. 2010
- Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation. 8:14-14. 2010
- Evaluation of health outcomes in osteoarthritis patients after total knee replacement: a two-year follow-up. Health and Quality of Life Outcomes. 8:87-87. 2010
- Support for a tax increase to provide unrestricted access to an Alzheimer's disease medication: a survey of the general public in Canada. BMC Health Services Research. 9:246. 2009
- The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. Journal of Medical Economics. 12:361-370. 2009
- Handling uncertainty in economic evaluations of patient level data: A review of the use of Bayesian methods to inform health technology assessments. International Journal of Technology Assessment in Health Care. 25:546-554. 2009
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Current Medical Research and Opinion. 25:1631-1633. 2009
- Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply. Current Medical Research and Opinion. 25:1632-1633. 2009
- P1‐208: How does the Canadian general public view moderate Alzheimer's disease? determination of health utility scores. Alzheimer's and Dementia. 5:p238-p238. 2009
- P1‐222: Canadians’ willingness to pay for Alzheimer's disease medications: Preliminary results of a study of the general public. Alzheimer's and Dementia. 5:p241-p241. 2009
- P2‐226: Public support for an annual tax increase to provide access to an Alzheimer's disease medication in Canada. Alzheimer's and Dementia. 5:p326-p327. 2009
- A review of the cost of cardiovascular disease. Canadian Journal of Cardiology. 25:e195-e202. 2009
- Approaches for Economic Evaluations of Health Care Technologies. Journal of the American College of Radiology. 6:307-316. 2009
- Conditionally Funded Field Evaluations and Practical Trial Design Within a Health Technology Assessment Framework. Journal of the American College of Radiology. 6:324-331. 2009
- Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making. Journal of the American College of Radiology. 6:332-342. 2009
- Health Technology Assessment for Radiologists: Basic Principles and Evaluation Framework. Journal of the American College of Radiology. 6:299-306. 2009
- Illustrating Economic Evaluation of Diagnostic Technologies: Comparing Helicobacter pylori Screening Strategies in Prevention of Gastric Cancer in Canada. Journal of the American College of Radiology. 6:317-323. 2009
- Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura. Clinical Therapeutics. 31:1082-1091. 2009
- Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care. 25:196-207. 2009
- In search of the evidentiary foundation of published Canadian economic evaluations (2001–06). International Journal of Technology Assessment in Health Care. 25:214-221. 2009
- A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. Value in Health. 12:245-252. 2009
- Excess Risk of Mortality and Complications Associated with Newly Diagnosed Cases of Diabetes in Ontario, Canada. Canadian Journal of Diabetes. 33:93-104. 2009
- Prevalence, Total and Excess Costs of Diabetes and Related Complications in Ontario, Canada. Canadian Journal of Diabetes. 33:35-45. 2009
- Reply. Journal of Vascular Surgery. 49:277-278. 2009
- The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.. Journal of Population Therapeutics and Clinical Pharmacology. 16:e346-e359. 2009
- A systematic review of the use of contingent valuation in Alzheimer's disease research. Dementia. 7:461-480. 2008
- The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis. Current Medical Research and Opinion. 24:3223-3237. 2008
- Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada. Journal of Vascular Surgery. 48:779-787. 2008
- Economic evaluations conducted by Canadian health technology assessment agencies: Where do we stand?. International Journal of Technology Assessment in Health Care. 24:437-444. 2008
- Universal or Targeted Screening for Fetal Alcohol Exposure: A Cost-Effectiveness Analysis. Journal of Studies on Alcohol and Drugs. 69:510-519. 2008
- Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement. Quality of Life Research. 17:595-601. 2008
- Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Canadian Journal of Ophthalmology. 43:213-217. 2008
- Effects of study design and trends for EVAR versus OSR. Vascular Health and Risk Management. Volume 4:1011-1022. 2008
- Money matters: what to look for in an economic analysis. Acta Orthopaedica. 79:1-11. 2008
- Effectiveness and Safety of Drug-Eluting Stents in Ontario. New England Journal of Medicine. 357:1393-1402. 2007
- Can an Educational Program Optimize PDE5i Therapy? A Study of Canadian Primary Care Practices. Journal of Sexual Medicine. 4:1404-1413. 2007
- Treatment Satisfaction with Sildenafil in a Canadian Real-Life Setting. A 6-Month Prospective Observational Study of Primary Care Practices. Journal of Sexual Medicine. 4:1414-1421. 2007
- Costs of New Atypical Antipsychotic Agents for Schizophrenia: Does Unrestricted Access Reduce Hospital Utilization?. Healthcare Policy. 3:58-79. 2007
- Managing multiple projects: a literature review of setting priorities and a pilot survey of healthcare researchers in an academic setting.. Perspectives in health information management / AHIMA, American Health Information Management Association. 4:4. 2007
- Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Current Medical Research and Opinion. 23:671-682. 2007
- A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets. Clinical Therapeutics. 29:519-528. 2007
- Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads. PharmacoEconomics (Auckland). 25:528-532. 2007
- Long-Term Cost-utility Analysis of a Multidisciplinary Primary Care Diabetes Management Program in Ontario. Canadian Journal of Diabetes. 31:205-214. 2007
- Painful Neuropathic Disorders: An Analysis of the RéGie De L’Assurance Maladie du QuéBec Database. Pain Research and Management. 12:31-37. 2007
- The humanistic burden of neuropathic pain in Canada. Journal of Medical Economics. 10:23-36. 2006
- Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: A Canadian perspective. Clinical Therapeutics. 28:1922-1934. 2006
- Measuring quality of life: The development and initial validation of the Patient-Reported Erectile Function Assessment instrument. International Journal of Technology Assessment in Health Care. 22:372-378. 2006
- Persistence and adherence to cholesterol lowering agents: Evidence from Régie de l'Assurance Maladie du Québec data. American Heart Journal. 152:164-169. 2006
- The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function.. Canadian Journal of Urology. 13:3016-3025. 2006
- The economic burden of neuropathic pain in Canada. Journal of Medical Economics. 9:55-68. 2006
- The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion. 21:2017-2028. 2005
- Erectile dysfunction in spinal cord injury: a cost-utility analysis. Journal of Rehabilitation Medicine. 37:358-364. 2005
- A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada.. Journal of Population Therapeutics and Clinical Pharmacology. 11:e179-e190. 2004
- A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs. Value in Health. 4:16-31. 2001
- A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.. Managed Care Interface. 13:88-94. 2000
- Antidepressant selection for major depressive disorder: The budgetary impact on managed care. Drug Benefit Trends. 12. 2000
- A pharmacoeconomic evaluation of major depressive disorder (Italy). Epidemiology and Psychiatric Sciences. 8:220-231. 1999
- TPDM6: DETERMINING COST DRIVERS IN A COSTEFFECTIVENESS ANALYSIS OF THREE TREATMENTS FOR OVERACTIVE BLADDER. Value in Health. 2:152-152. 1999
- PCV10: A HEALTH ECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN BELGIUM. Value in Health. 2:27-27. 1999
- A health economic evaluation of hormone replacement therapy in belgium. International Journal of Fertility and Menopausal Studies. 43:224. 1998
- Evaluation of low acuity patients discharged from a virtual emergency department at a major urban academic health sciences centre in Toronto, Canada.. International Journal of Population Data Science. 7:1926.
- French Translation of the 2022 Version of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Canadian Journal of Health Technologies. 3.
- Platform, Basket, and Umbrella Trial Designs: Issues Around Health Technology Assessment of Novel Therapeutics. Canadian Journal of Health Technologies. 2.
- Platform, Basket, and Umbrella Trial Designs: Stakeholder Perspectives of Novel Therapeutics. Canadian Journal of Health Technologies. 2.
- Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives. Canadian Journal of Health Technologies. 2.
preprints